

HER1 R497K and *HER2* I655V polymorphisms are linked to development of breast cancer

Naglaa R. AbdRaboh^{a,*}, Hanan H. Shehata^a, Manal B. Ahmed^a and Fatehia A. Bayoumi^b

^aDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

^bDepartment of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Abstract.

BACKGROUND: Polymorphism of the genes of Human Epidermal growth factor receptor1 (*HER1*) and receptor2 (*HER2*) have been reported to be linked to pathogenesis of several malignant tumors but still there is contradiction regarding their association with breast cancer.

OBJECTIVE: In this case control study we aimed to analyze the frequency of *HER1* R497K (rs 11543848) and *HER2* I655V (rs 1136201) Polymorphisms in breast cancer.

SUBJECT AND METHOD: The frequency of *HER1* Arg(R) 497Lys (K) and *HER2* Ile (I) 655Val (V) polymorphisms were tested in 64 breast cancer patients and 86 normal control by polymerase chain reaction followed by restriction fragment polymorphism detection. Immunohistochemical analysis was done for *HER2* protein on the available 18 malignant tissue samples.

RESULTS: *HER1* 497K and *HER2* 655V variant had significantly increased breast cancer risk (OR = 2.6, 95% CI 1.6–4.2, OR = 2.2, 95% CI 1.2–4.1, $p < 0.05$) respectively. Moreover, combined *HER1*K497 and *HER2* V655 variant was detected in 26.6% malignant in comparison to 8.14% of control group (OR = 4.1, 95% CI 1.58–10.57), but, no significant association was noticed between both Polymorphisms and clinicopathological features of the disease. As regard *HER2* immunohistochemical expression no significant correlation was revealed with *HER2* 655V polymorphism.

CONCLUSIONS: Our findings suggest that *HER1* 497K and *HER2* 655V polymorphisms are potential risk factor for development of breast cancer.

Keywords: *HER1* gene, *HER2* gene, polymorphism, *HER2* protein expression, breast cancer

1. Introduction

Recently enormous number of researches has been focused on identification of genetic predisposition to different complex diseases particularly cancer. The incidence of breast cancer has been progressively increased with estimated 229,060 new diagnosis and 39,510 deaths per year in the United States [1]. Molecular

genetic analysis of breast cancer indicated the implication of various structural and functional genetic alterations in cancer development. Hence identification of molecular characteristics of breast cancer enables more accurate prediction of the course of the disease and response to chemotherapy [2].

Growth, differentiation, and motility of various tumor cells are remarkably related to growth factor receptors [3]. An important family of growth factor receptors is Epidermal Growth Factor Receptor EGFR, or *erbB* family, including four distinct transmembrane tyrosine kinase receptors, known as *HER1* (EGFR, *erbB1*), *HER2* (*erbB2*, *neu*), *HER3* (*erbB3*), and *HER4*

*Corresponding author: Naglaa R. AbdRaboh, Department of Medical Biochemistry and Molecular Biology, Ain Shams Faculty of Medicine, Cairo, Egypt. Tel.: +20 971 508 778 149; Fax: +20 971 554 045 467; E-mail: naglaoda@hotmail.com.

(erbB4) [4]. Their activation leads to downstream effect in gene expression, cellular proliferation, cell growth, differentiation, and survival [5].

Alteration of genes and aberration of signaling pathway of *HER1*, and *HER2* have been frequently implicated in carcinogenesis of a variety of solid tumors [6]. Uzan et al., 2009 found that *HER1* and *HER2* overexpression are associated with poor prognosis in breast cancer [4], as well as gene amplification of *HER2* in 10 to 25% of invasive breast cancer and unfavorable effect on the course of the disease [7].

Single nucleotide polymorphisms (SNPs) are the commonest sources of human genetic variation which contribute to susceptibility to malignant transformation [8]. A SNP at codon 497 of *HER1* gene leads to Arg (R) to Lys (K) substitution in the extracellular domain known as *HER1* R497K (rs 11543848) has been identified in breast cancer and other EGFR expressing tumors such as gliomas, lung and colorectal cancer [9].

Another SNP at codon 655 of *HER2* indicates a isoleucine-to-valine substitution (I655V) in the transmembrane domain has been associated with risk of breast cancer [10]. The molecular mechanism of the involvement of *HER2* I655V (rs 1136201) polymorphism in the process of carcinogenesis is still under investigation. The specific concern about HER family comes from demonstrated improvement of overall survival in advanced *HER2* overexpressing breast cancer patients who received *HER2* monoclonal antibody trastuzumab which bind extracellular part of *HER2* [11], and the clinical activity of anti*HER1* was observed in tumors with low expression of *HER1* [12].

Hsieh et al., 2012 reported that *HER1* R497K polymorphism could be a key determinant of increased response to cetuximab-based chemotherapy and a longer survival in colorectal cancer patients [13]. Gerger et al., 2011 suggested that *HER2* I655V polymorphism may identify patients with metastatic colorectal cancer likely to experience better outcome when treated with cetuximab [14]. In addition Williams et al., 2012 found potential predictive value of *HER2* I655V polymorphism for overall survival in advanced cancer of the head and neck [15].

The proved interaction between different HER family has directed us to evaluate the possible link between *HER1* R497K and *HER2* I655V polymorphisms on development of breast cancer, and the possible influence of both polymorphisms on disease aggressiveness.

2. Subjects and methods

The current study has been performed between 2010 and 2012, it included 64 females pathologically proven as breast cancer with mean age (52.1 ± 13.8) selected from patients who were admitted in department of Surgery Ain Shams University hospitals. They were staged according to TNM classification of the American Joint Committee on cancer (AJCC) [16], and graded by the Nottingham grading system [17]. The study was performed in accordance with Declaration of Helsinki, and was approved by the Research Ethics Committee of Ain Shams University, Cairo, Egypt. An informed consent was obtained from all patients. The control group included 86 normal females with mean age (44.5 ± 8.1). all participates were subjected to history taking and withdrawal of 10 ml venous blood samples which were collected in EDTA containing tubes for DNA extraction. Fresh breast tissue samples were taken from tumors of 18 women subjected to surgical treatment and they were kept in 10% formaline for immunohistochemical analysis. An informed consent was taken from all participates. The clinicopathological features of patients were collected from patient's pathological reports.

2.1. DNA extraction

Genomic DNA was extracted from white blood cell pellets of venous blood samples collected on EDTA tubes by salting out extraction method using wizard genomic DNA extraction kit from Promega UK. Red blood cell lysis was done by using red cell lysis buffer (20 mM Tris-CL pH 7.6) followed by centrifugation. Nuclei lysis was carried by cell lysis buffer (10 mM Tris-CL pH 8.0, 1 mM EDTA pH 8.0, 0.1% (w/v) SDS) and proteinase K (20 mg/ml) followed by centrifugation. Protein was precipitated by protein precipitation solution (60 ml of 5 M potassium acetate, 11.5 ml of glacial acetic acid, 28.5 ml of water) followed by centrifugation. Finally DNA was precipitated by isopropanol and then ethanol 70% and rehydrated in TE buffer (pH 7.6). The DNA purity and concentration were determined by spectrophotometer measurement of absorbance at 260 and 280 nm [18]. The extracted DNA was stored at -20°C .

2.2. Genotyping of *HER1* R497K polymorphism

The R497K (G \rightarrow A) polymorphism of the *HER1* gene was examined by PCR-RFLP method as de-

Table 1
Pathological parameters of malignant patients

Malignant samples		n (%)
Age year (mean ± SD)		(52 ± 13.7)
Stage	IIA	14 (21.9)
	IIB	16 (25.0)
	IIIA	18 (28.1)
	IIIC	4 (6.25)
	IV	12 (18.8)
Grade	I	6 (9.4)
	II	38 (59.4)
	III	20 (31.2)
Distant metastasis	Negative	52 (81.3)
	Positive	12 (18.7)
Lymph nodes	Negative	32 (50.0)
	Positive	32 (50.0)
Tumor size	≤ 2 cm	46 (71.9)
	> 2 cm	18 (28.1)
Pathology	Duct carcinoma	44 (68.7)
	Lobular carcinoma.	6 (9.7)
	Mixed duct and lobular	6 (9.4)
	Poorly differentiated tumor	8 (12.5)
HER2 expression	Weak (score 0, 1)	9 (50.0)
	Moderate (score2)	7 (39.0)
	Severe (score3)	2 (11.0)

n: number; SD: standard deviation.

scribed previously [19]. Briefly, 50–100 ng of genomic DNA was amplified in 50 µl reaction mixture containing, 20 pmol/L (forward primer, 5'-TGCTGTGACCC-ACTCTGTCT-3' and reverse primer, 5'-CCAGAAGG-TTGCACTTGTC-3') and 25 µL of Master Mix containing 2.5 units of Taq DNA polymerase, 1 × PCR buffer 50 mM Tris-HCl (pH 9.0); 50 mM NaCl; 5 mM MgCl₂; 200 µM of each dNTP. After initial denaturation at 95°C for 3 min, the reaction was carried out at 94°C denaturation for 1 min, 59°C annealing for 1 min, and 72°C extension for 1 min for a total of 35 cycles. PCR products after being digested by *Bst*N1 restriction enzyme (Promega UK) at 60°C for 16 h were separated on 3% ethidium bromide – stained agarose gels. *Bst*N1 digestion gave three fragments 38, 50, and 67 bp for Arg allele, and two fragments 38, 117 bp for Lys allele; The gel was documented by Doc. Photo capture software version 12.5 by using uv transilluminator and camera from (Vilber Loumart- France).

2.3. Genotyping of HER2 V655 polymorphism

For the *HER2* V655 polymorphism, 50–100 ng of genomic DNA was amplified in 50-µl reaction mixture containing, 20 pmol forward 5'AGAGCGCCAGCC-TCTGACGTCCAT-3', and reverse 5'- TCCGTTTCCT-GCAGCAGTCTCCGCA-3' [20] and 25 µL of Master Mix containing 2.5 units of Taq DNA polymerase, 1 × PCR buffer 50 mM Tris-HCl (pH 9.0); 50 mM

NaCl; 5 mM MgCl₂; 200 µM of each dNTP. The samples were denatured for 6 min at 94°C. This was followed by 35 cycles of denaturation for 30 s at 94°C, annealing for 1 min at 56°C and extension for 1 min at 72°C with a final extension for 7 min at 72°C. For RFLP analysis, 5 µL of each PCR product was digested with 4 U *Bsm*AI (Promega UK) at 55°C for 2 h. *Bsm*AI digestion gave fragments of 116 bp and 32 bp for the Val (GTC) allele and a single 148 bp fragment for the Ile (ATC) allele. Fragments digested with *Bsm*AI were subjected to electrophoresis on a 3% agarose gel, stained with ethidium bromide and visualized under UV light [21].

2.4. Immunohistochemical protein expression of HER2

The protein expression level of HER2 was assessed using immunohistochemistry on formalin fixed, paraffin-embedded tumor tissues. Reactions were performed with anti-c-erbB-2 polyclonal antibody (DAKO, Glostrup-Denmark) using the streptavidin biotin peroxidase method along with DAB as chromogen by Ventana-NexES IHC automatic immunostainer.

HER2 was scored using a modification of the HercepTest 0–3 + scoring system [22], HER2 was scored as 0 (absence of staining), 1 + (any amount of partial membranous staining), 2 + (weak to moderate complete membranous staining in more than 10%, or strong complete membranous staining in 30% or less), or 3 + (strong complete membranous staining in more than 30%). The IHC staining results were correlated with multiple clinicopathologic variables. Clinical guidelines provide specific criteria for positive (3 +), equivocal (2 +), and negative (0 or 1 +) IHC staining results [23]. Ki67 immunostaining was performed to assess the proliferative activity of the tumor cells.

2.5. Statistical analysis

Data were tested for statistical significance by using Statistical Package for the Social Sciences software system SPSS-17 statistical software (SPSS, Chicago, IL). Chi-square or Fisher exact test was used to analyze differences in allele and genotype frequencies, as well as association between each of the SNP and clinicopathological parameters. Hardy-Weinberg equilibrium (HWE) was tested by comparing the observed and expected genotype frequencies contingency table analysis (χ^2 -test) for the cases and controls separately. The strength of association of the evaluated gene polymor-

Table 2
Frequency of *HER1* R497K and *HER2* I655V alleles and genotypes in breast cancer patients ($n = 64$) and control groups ($n = 86$)

	Cases n (%)	Control n (%)	OR (CI)	p -value
<i>HER1</i> R497K				
Codominant inheritance				
497RR	11 (17.2)	48 (55.8)	1.0 (Reference)	
497RK	50 (78.1)	36 (41.9)	4.9 (2.56 – 9.76)	< 0.01*
497KK	3 (4.7)	2 (2.3)	6.5 (0.97 – 43.9)	> 0.05
Recessive inheritance				
497RK + RR vs KK	61 (95.3)	84 (97.7)	2.1 (0.33–2.70)	0.01*
Dominant inheritance				
497KK + RK vs RR	53 (82.8)	38 (44.2)	6.1 (2.79–13.21)	< 0.01*
Allele frequency				
497 R allele	72 (56.0)	132 (76.7)	1.0 (Reference)	
497K allele	56 (44.0)	40 (23.3)	2.6 (1.56–4.21)	< 0.01*
<i>HER2</i> I655V				
Codominant inheritance				
655II	39 (60.9)	67 (77.9)	1.0 (Reference)	
655IV	21 (32.8)	18 (20.9)	2.0 (0.95–4.21)	> 0.05
655VV	4 (6.3)	1 (1.2)	6.8 (0.74–63.6)	> 0.05
Recessive inheritance				
655 IV + II vs VV	60 (93.7)	85 (98.8)	5.7 (0.61–51.9)	> 0.05
Dominant inheritance				
655 IV + VV vs II	25 (60.9)	19 (77.9)	2.3 (1.11–4.62)	< 0.05*
Allele frequency				
655I allele	99 (77.3)	152 (88.4)	1.0 (Reference)	
655V allele	29 (22.7)	20 (11.6)	2.2 (1.19–4.15)	0.01*
Combined <i>HER1</i> R497K and <i>HER2</i> I655V Mutation				
a) 497RR/655II	5 (7.8)	37 (43.02)	1.0 (Reference)	
b) 497K or 655V	42 (65.6)	42 (48.84)	7.4 (2.65–20.67)	< 0.01*
c) 497K and 655V	17 (26.6)	7 (8.14)	17.9 (4.98–64.85)	< 0.01*
c vs (a + b)			4.1 (1.58–10.57)	< 0.01*
(c + b) vs a			8.9 (3.25–24.4)	< 0.01*

* $p < 0.05$ is significant, n = number, OR = Odd ratio, 95% CI = 95% confidence interval, K = lysine (mutant allele), R = arginine, V = valine (mutant allele), and I = isoleucine; a) Non mutated 497RR/655II genotype; b) Isolated mutation either 497K or 655V alleles; c) Combined 497K and 655V alleles.

phism with breast cancer was measured by the odd ratio (OR) and corresponding 95% confidence interval (95% CI) and two sided p value. P value < 0.05 was considered statistically significant.

3. Results

The present study was performed on venous blood samples withdrawn from 150 subjects (64 malignant cases with mean age (52 ± 13.7) and 86 normal control individuals with mean age (44.6 ± 7.9) with no significant difference between mean age of both groups $P > 0.05$. The clinicopathological criteria of malignant cases are shown in Table 1). All of the samples were subjected to analyses for two gene polymorphisms *HER1* R497K, and *HER2* I655V by using RFLP followed by agarose gel electrophoresis. Tissue samples of 18 cases were available for immunohistochemical analysis for *HER2* protein expression.




Fig. 1. Agarose electrophoresis for detection of *HER1* Arg497Lys polymorphism: Lane 1 is 25 bp DNA ladder, lanes 3,6,8,10,13,14,15 are homozygous genotype Arg/Arg showing three bands 38, 50, 67 bp, lanes 4,5,7,11,12 are heterozygous genotype Arg/Lys showing four bands 38, 50, 67, and 117 bp, lane 9 is homozygous genotype Lys/Lys with two bands 38, 117 bp.

3.1. *HER1* R497K polymorphism

The gel electrophoresis for *HER1* R497K was shown in Fig. 1 after restriction with *Bst*NI enzyme, homozygous genotype Arg/Arg had three fragments with 38, 50, and 67 bp length; homozygous Lys/Lys had two fragments 38, 117 bp length and heterozygous genotype Arg/Lys had four fragments 38, 50, 67, and

Table 3
Association of HER1 R497K and HER2 I655V polymorphisms with clinicopathological parameters of breast cancer patients

HER1 R497K		RR genotype <i>n</i> (%) ^a	RK + KK genotype <i>n</i> (%) ^b	Total	OR (CI)
Stage	Late (IIIA, B, IV)	6 (17.6)	28 (82.4)	34	0.9 (0.26–3.43)
	Early (IIA, IIB)	5 (16.7)	25 (83.3)	30	
Distant metastasis	Positive	1 (8.3)	11 (91.7)	12	2.6 (0.30–22.7)
	Negative	10 (19.2)	42 (80.8)	52	
Grade	High	2 (10)	18 (90)	20	2.3 (0.45–11.8)
	Low	9 (20.5)	35 (79.5)	44	
Tumor size	> 2 cm	2 (11.1)	16 (88.9)	18	1.9 (0.37–10.03)
	≤ 2 cm	9 (19.6)	37 (80.4)	46	
Lymph nodes	Positive	6 (18.8)	26 (81.3)	32	0.80 (0.22–2.95)
	Negative	5 (15.6)	27 (84.4)	32	
Age	≥ 45	8 (19)	34 (81)	42	0.67 (0.16–2.83)
	< 45	3 (13.6)	19 (86.4)	22	
HER2 I655V		II genotype <i>n</i> (%) ^c	VV + IV genotype <i>n</i> (%) ^d	Total	OR (CI)
Stage	Late (IIIA, B, IV)	24 (70.6)	10 (29.4)	34	0.42 (0.15–1.16)
	Early (IIA, IIB)	15 (50)	15 (50)	30	
Distant metastasis	Positive	5 (41.7)	7 (58.3)	12	2.64 (0.74–9.53)
	Negative	34 (65.4)	18 (34.6)	52	
Grade	High	15 (75)	25% (5)	20	0.43 (0.15–1.26)
	Low	24 (54.5)	45.5% (20)	44	
Tumor size	> 2 cm	12 (66.7)	6 (33.3)	18	0.70 (0.22–2.22)
	≤ 2 cm	27 (58.7)	19 (41.3)	46	
Lymph nodes	Positive	23 (72)	9 (28)	32	0.39 (0.13–1.10)
	Negative	16 (50)	16 (50)	32	
Her2 gene expression <i>n</i> = 18	Strong + medium	4 (44.4)	5 (55.6)	9	1.56 (0.24–10.03)
	Weak	5 (55.6)	4 (44.4)	9	
Age	≥ 45	25 (59.5)	17 (40.5)	42	1.46 (0.49–4.32)
	< 45	15 (68.2)	7 (31.8)	22	

All parameters showed $p > 0.05$ which is non-significant, n = number, OR = Odd ratio, CI = 95% confidence interval; a: number of cases with RR genotype = 11; b: number of cases with RK + KK genotype = 53; c: number of cases with II genotype = 39; d: number of cases with VV + IV genotype = 25.




Fig. 2. Agarose gel electrophoresis for detection of HER2 Ile655Val polymorphism: Lane 1 is Val/Val homozygous genotype with single band at 116 bp, lanes 2,3,4,6,10 are Ile/Ile homozygous genotype with one band 148 bp, lanes 5,8,9 are Ile/Val heterozygous genotype with two bands 116, 148, and lane 7 is 50 bp DNA ladder.

117 bp length. The frequency of *HER1* R497K genotypes were consistent with Hardy Weinberg equilibrium (HWE) in control group ($\chi^2 = 2.57$, $p^2 = 0.59$, $2pq = 0.35$, $q^2 = 0.05$), but malignant group was deviated from HWE ($\chi^2 = 22.8$, $p^2 = 0.32$, $2pq = 0.49$, $q^2 = 0.19$). As shown in Table 2) the frequency of K allele was significantly higher in malignant cases (44%) than in control group (23.3%), $p < 0.01$. Moreover the frequency of *HER1* R497K heterozygous genotype

R/K and K containing genotypes (KK + KR) versus homozygous RR were significantly higher in malignant compared to control group ($p < 0.01$).

3.2. *HER2* I655V polymorphism

As shown in Fig. 2, agarose gel electrophoresis of *HER2* I655V polymorphism after restriction with *BsmA1* enzyme. Homozygous Val/Val (V/V) genotype has single band with 116 bp length, Homozygous Ile/Ile (I/I) genotypes has one band 148 bp, and heterozygous I/V has two bands 116, and 148 bp. The frequency of *HER2* I655V genotypes was not deviated from HWE both in control group ($\chi^2 = 0.03$, $p^2 = 0.77$, $2pq = 0.21$, $q^2 = 0.014$) and malignant group ($\chi^2 = 0.26$, $p^2 = 0.59$, $2pq = 0.35$, $q^2 = 0.05$). As indicated in Table 2), *HER2* I655V genotypes was significantly higher for V containing genotypes (V/V + I/V) compared to homozygous I/I genotype in malignant group than in control group ($p < 0.05$). Similarly,

Table 4
Association of *HER1* R497K and *HER2* I655V polymorphisms with histopathological types of breast cancer samples

Polymorphism	Histopathological types			
	Duct carcinoma <i>n</i> (%)	Lobular carcinoma <i>n</i> (%)	Mixed duct and lobular <i>n</i> (%)	Poorly differentiated tumor <i>n</i> (%)
<i>HER1</i> R497K				
497RR	6(13.6)	0(0)	3(50.0)	2(25)
497KK + RK	38(86.4)	6(100)	3(50.0)	6(75)
<i>P</i> value	> 0.05			
497R allele	47/88(53.4)	6/12(50.0)	9/12(75)	10/16(62.5)
497K allele	41/88(46.6)	6/12(50.0)	3/12(25)	6/16(37.5)
<i>P</i> - value	> 0.05			
<i>HER2</i> I655V				
655II	25(56.8)	6(100)	6(100)	4(50.0)
655VV + VI	19(43.2)	0(0)	0(0)	4(50.0)
<i>P</i> - value	< 0.05*			
655I allele	65/88(73.9)	12/12(100)	12/12(100)	10/16(62.5)
655V allele	23/88(26.1)	0/12(0)	0/12(0)	6/16(37.5)
<i>P</i> - value	0.01*			

**p* < 0.05 is significant.




Fig. 3. Shows strong membranous expression of Her-2 on the malignant ductal epithelial cells and negative stromal expression in a case of invasive ductal carcinoma, (x200 Hx&E; x400, PAP).

the frequency of V allele was significantly higher in malignant patients (22.7%) in comparison to control group (11.6%), *p* < 0.01.

3.3. Combined *HER1* R497K and *HER2* I655V polymorphisms

As seen in Table 2 the group at which there was combined variants (497K/655V) showed marked increased risk of breast cancer, it was detected in 26.6% of malignant in comparison to 8.14% of control (OR = 4.1, 95% CI 1.58–10.57, *P* value < 0.01), when compared to other combinations of genotypes.

3.4. The relation of *HER1* R497K and *HER2* I655V polymorphisms to clinicopathological parameters

No significant association could be detected between the frequency of polymorphisms and any of the evaluated parameters (Table 3). Regarding histopathological types there was significant difference for *HER2* 655V allele and genotype which was higher in poorly differentiated tumors in comparison to other types (Table 4).

3.5. Immunohistochemical expression of *HER2* protein

As shown in Figs 3–5 the expression was categorized into three degrees, strong expression have given




Fig. 4. Invasive Lobular carcinoma with moderate membranous expression of Her-2 on the malignant lobular epithelial cells (x200, PAP).




Fig. 5. Shows weak membranous expression of Her-2 on the proliferating ductal epithelial cells and negative stromal expression in a case of intra-ductal fibroadenoma, (x200, x400, PAP).

score 3 (Fig. 3) and it was detected in 2 samples out of the analyzed 18 malignant specimens (11%) of malignant, moderate expression with score 2 was found in 7 samples (39%) (Fig. 4), and weak expression with score 0, 1 found in 9 samples (50%) (Fig. 5). No significant association was found between HER2 overexpression (score 3) and HER2 I655V Polymorphism as overexpression was found in 5 samples (55.6%) of 655V containing genotypes as compared to 4 samples (44.4%) of homozygous 655II genotype ($p > 0.05$) (Table 3).

4. Discussion

Genetic mutation has been contributed to the susceptibility of malignant transformation including breast

carcinomas [10,24]. Genetic polymorphism and protein over-expression of erbB (*HER*) signaling system has been widely studied and proved to be associated with pathogenesis of many tumors [25]. Indeed, an interaction between different HER receptors was confirmed in malignant alteration and had been implicated in responsiveness of adjuvant cytotoxic chemotherapy [26,27]. Identification of new genetic and environmental factors that affect susceptibility to breast cancer would yield further insight into breast tumorigenesis, and provide target for development of new therapeutic approaches, in this respect HER receptor genes are plausible candidate genes to recognize tumors that are likely to respond to HER directed therapies [28].

HER1 (EGFR) was the first tyrosine kinase receptor to be directly linked with human cancer. The *HER1* gene maps to 7p11.2-p2 and encodes a 170 kDa trans-

membrane protein [29]. *HER1* gene amplification has been described in oligodendrogliomas [30], glioblastomas [31], lung carcinomas [32], gastric carcinomas [33], and breast carcinomas [34,35]. The *HER2* gene maps to chromosome 17q21 and encodes a 185 kDa glycoprotein. It is reported to be amplified and overexpressed in several types of human tumors, including about 30% of all breast carcinomas [35–37].

In the current study we analyzed the frequency of *HER1* 497K and *HER2* 655V variants in breast cancer patients, our results revealed significant increase of both variants in comparison to control group ($p < 0.05$) with increased risk of breast cancer (OR = 2.6, 95% CI 1.6–4.2/OR = 2.2, 95% CI 1.2–4.1) for *HER1* 497K allele, and *HER2* 655V allele respectively.

Some of earlier reports have revealed that the presence of *HER2* 655V polymorphism is associated with increased risk of breast cancer including a meta-analysis performed by Tao et al., 2009 on 20 eligible reports including 10,642 cases and 11,259 controls showed higher frequency of V allele in breast cancer cases (OR = 1.1, 95% CI 1–1.2, $p = 0.04$) [38], a further meta-analysis study by Lu et al., 2010 included 11504 cases and 12538 controls, in subgroup analysis by ethnicity they found significant association among Africans (OR = 8.6, 95% CI 1.9–38.5), and Asians (OR = 1.2, 95% CI 0.01–1.38) [39]. Xie et al., 2000 recorded very high risk of *HER2* 655V polymorphism in relation to breast cancer in Chinese population (OR 14.1, 95% CI 1.8–113.4) of the V/V versus I/I genotype [40]. Kruszyna et al., 2010 suggested that *HER2* 655V polymorphism may be susceptibility biomarker of breast cancer among older women [41], while Millikan et al., 2003 reported a twofold increased risk of breast cancer associated with V/V or V/I genotype compared with I/I genotype among women living in North Carolina (United States) who were both less than 45 years of age and reported a positive family history of breast cancer (OR 2.3 95% CI 1–5.3) [42]. Similarly, the results of the present study was correlating with previous reports of Baxter and Campbell 2001; Mackean Cowdin et al., 2001; Montgomery et al., 2003; Lee-Hoeflich et al., 2008; and Ozturk et al., 2012 [43–46,20].

Several studies have shown conflicting results with the majority of them showing no risk association with *HER2* 655V polymorphism as those of Montgomery et al., 2003; Kara et al., 2010; Dahabreh and Murray 2011; and Ma et al., 2011 [47–49,45]. These studies were performed on different ethnic groups at which same polymorphisms have different somatic varia-

tions, therefore they may not be reliable to compare to our study which has investigated HER polymorphisms in Arabic Egyptian subjects.

Actually, limited number of studies have been focused on *HER1* 497K polymorphism in cancer patients, and we couldn't find any record in breast cancer, on the other hand; the impact of and *HER2* 655V polymorphisms on progression of breast cancer is another controversial point supported by study of Naidu et al., 2008 who found significant positive correlation between *HER2* 655V polymorphism and lymph node involvement in breast cancer patients; alternatively [50], Ozturk et al., 2012 and Akisik and Dalay 2004 have observed lack of association between *HER2* V allele and clinicopathological parameters as tumor type, grade, and stage [46,21].

In the current study there was lack of association between the frequency of *HER1* 497K polymorphism and all evaluated clinicopathological parameters; nevertheless, for *HER2* 655V polymorphism there was significant difference between histopathological types as the frequency of V allele was significantly higher ($p < 0.05$) in poorly differentiated tumors (37.5%) as compared to 26.1% of duct carcinoma, and complete absence in lobular and mixed carcinomas. These findings may imply the potential effect of *HER2* 655V polymorphism on tissue differentiation which is considered a poor prognostic feature of the disease.

Regarding *HER1* 497K polymorphism our findings disagreed with those of Khallel et al., 2009 who observed lack of risk association between *HER1* 497K allele and breast cancer in 148 Tunisian patients, but they found positive correlation with both tumor grade and nodular status [51].

The comparison of *HER1* 497K and *HER2* 655V genotypes and alleles in the present study have shown a pronounced increased frequency of combined *HER1* 497K and *HER2* 655V allele variants in 26.6% of malignant cases versus 8.1% of control individuals (OR = 4.1, 95% CI 1.58–10.57, $p < 0.01$), this elevation of combined mutation may reflect a possible genetic background of active HER receptor co-expression and communication which have great bear on the process of carcinogenesis.

At the present study we were able to test immunohistochemical expression of HER2 receptor protein, with over expression recorded in 11% of the analyzed breast cancer tissues with a relevant lack of association with *HER2* 655V polymorphism. Previous literatures have proved that over-expression of HER2 protein is almost always accompanied by *HER2* DNA amplification [52,

53], but we couldn't find recorded results for association with *HER2* 655V polymorphism.

Most likely *HER2* receptor induce tumorigenesis through number of signaling pathways [54], the simplest mechanistic model is through elevation of kinase activity and over phosphorylation of itself and cellular substrates. The second model is increase of *HER2* hetero-dimerization with *HER1* and *HER3* [55,56] that interfere with *HER1* endocytic degradation with subsequent increase of signaling duration and potency [57]. A third mechanism through alternative *HER2* transcript named Δ *HER2* which increase ligand independent signaling activity and increase transforming potency [58]. The last known mechanism is activation of interacting SH2 containing protein (src kinase) which acts as second messenger of *HER2*. Elevated activity of src kinase is seen in many tumors including breast cancer with or without *HER2* over-expression [59].

The results of current study suggest that implication of *HER2* 655V polymorphism in carcinogenesis may preferentially occur through functional modification rather than increase protein expression by increasing the formation of active *HER2* heterodimer causing alteration of tyrosine kinase activity. Indeed, several limitations should be considered in the present study, as limited number of samples, lack of data about some prognostic markers as hormonal receptors, moreover, disease free survival which have not been examined interfered with reliable evaluation of prognostic value of investigated SNPs in breast cancer.

Finally, we concluded that *HER1497K* and *HER2* 655V polymorphisms may be considered susceptibility genetic markers for the risk of breast carcinogenesis but not suitable indicators of disease aggressiveness. *HER2* 655V polymorphisms may have qualitative rather than quantitative stimulatory effect on *HER2* protein that needs further exploration, with concern of other erbB receptors.

Acknowledgment

The authors wish to express their gratitude to Dubai Medical College for financial and laboratory support. Our sincere appreciation for the great effort of Dr. Mohammed El Shennawy, from department of general surgery, Ain shams hospitals, for helping in collection of blood and tissue samples and recording of required data.

References

- [1] R. Siegel, D. Naishadam, and A. Jemal, Cancer statistics, 2012, *CA Cancer J. Clin.* (2012), 62:10-29.
- [2] N. Normanno, M. Di Maio, E. De Maio, A. De Luca, A.de Matteis, A. Giordano, and F. Perrone, Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. *Endocr Relat Cancer.* (2005), 12:721-747.
- [3] P. Casalini, M. Iorio, and E. Galmozzi, Role of *HER* receptors family in development and differentiation, *J Cell Physiol.* (2004), 200:343-350.
- [4] C. Uzan, E. Darai, A. Valent, O. Graesslin, A. Cortez, R. Rouzier, and P. Vielh, Status of *HER1* and *HER2* in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. *Virchows Arch.* (2009), 454:525-529.
- [5] J. Laskin, and A. Sandler, Epidermal growth factor receptor: a promising target in solid tumors. *Cancer Treatment Reviews.* (2004), 30(1):1-17.
- [6] F. Ciardiello, and G. Tortora, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, *Clin Cancer Res.* (2001), 7:2958-70.
- [7] S.Menard, P. Casalini, M. Campiglio, S. Pupa, R. Agresti, E. Tagliabue, *HER2* overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer, *Ann Oncol.* (2001), 12(Suppl 1):S15-S19.
- [8] National Centre for Biotechnology Information (NCBI): Single nucleotide polymorphism database. A (2011), available online: [Http://www.ncbi.nlm.nih.gov/projects/snp](http://www.ncbi.nlm.nih.gov/projects/snp).
- [9] W.S. Wang, P.M. Chen, T.J. Chiou, J.H. Liu, J.K. Lin, T.C. Lin, H.S. Wang, Y. Su, Epidermal growth factor receptor r497k polymorphism is a favourable prognostic factor for patients with colorectal carcinoma, *Clin. Cancer Res.* (2007), 13:3597-3604.
- [10] H. El-Mougy, O. Sarhan, W. Abdel Fatah, and O. Khorshid, Plasma Human Epidermal Growth Factor Receptor-2 levels (*HER-2*) and *HER-2* codon 655 polymorphism in Females Suffering from Breast Cancer, *J. Am. Sci.* (2012), 8(4): 546-552.
- [11] D. Osoba, D. J. Slamon, M. Burchmore, and M. Murphy, Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer, *J. Clin. Oncol.* (2002), 20:3106-3113.
- [12] M. Ranson, L.A. Hammond, D. Ferry, M. Kris, A. Tullo, P.I. Murray, V. Miller, S. Averbuch, J. Ochs, C. Morris, A. Feyereislova, H. Swaisland, and E.K. Rowinsky, ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, is well tolerated and active in patients with solid malignant tumors: results of a phase I trial, *J Clin Oncol.* (2002), 20:2240-2250.
- [13] Y. Hsieh, C. H. Tzeng, M. H. Chen, P. M. Chen, and W. S. Wang, Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in *KRAS* wild-type colorectal cancer patients treated with cetuximab-based chemotherapy, *Cancer Sci.* (2012), 103:791-796.
- [14] A. Gerger, P. O. Bohanes, D. Yang, T. Winder, Y. Ning, M. J. Labonte, D. J. Mauro, C. Langer, E. K. Rowinsky, and H. Lenz, Human epidermal growth factor receptor-2 (*HER2*) Ile655Val single nucleotide polymorphism (SNP) is associated with gender-specific outcome in patients with metastatic colorectal cancer (mCRC) treated with cetuximab in a phase II study (IMCL-0144), *Clin Oncol.* (2011), 29(4): abstr 441.
- [15] J. Williams, L. Obermann, G. Ehninger, and E. Goekkurt, Polymorphisms of the Epidermal Growth Factor Receptor and

- Survival in Patients with Advanced Cancer of the Head and Neck, *Anticancer Res.* (2012), 32(2):421-425.
- [16] Sixth Edition of the AJCC Cancer Staging Manual. American Cancer Society, CA Cancer J Clin. (2006), 56:37-47.
- [17] A. Emad, E. Rakha Maysa, H. S. Andrew, W. E. Christopher, J. G. Matthew, W. B. Roger, and O. E. Ian, Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma, *Journal of Clinical Oncology* (2008), (26):19.
- [18] S. Josef, W. R. David, I. Nina, and A. J. Kaaren, Molecular Cloning: Rapid Isolation of Mammalian DNA, Cold Spring Harbour Laboratory Press. New York (2002), p628-630.
- [19] K. Martin, M. Radlmayr, R. Borchers, M. Heinzlmann, and C. Folwaczny, Candidate genes colocalized to linkage regions in inflammatory bowel disease, *Digestion*; (2002), 66:121-6.
- [20] R. McKean-Cowdin, L. N. Kolonel, M. F. Press, M. C. Pike, and B. E. Henderson, Germ-line HER-2 variant and breast cancer risk by stage of disease, *Cancer Res.* (2001), 61:8393-8394.
- [21] E. Akisik, and N. Dalay, Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk, *Exp Mol Pathol.* (2004), 76(3):260-3.
- [22] R. Bast, P. Ravdin, and D. Hayes, 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology, *J Clin Oncol.* (2001), 19:1865-1878.
- [23] A. Wolff, M. Hammond, and J. Schwartz, American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, *J Clin Oncol.* (2007), 25:118-145.
- [24] E. Papadopoulou, K. Simopoulos, G. Tripsianis, I. Tentes, K. Anagnostopoulos, E. Sivridis, G. Galazios, and A. Kortsaris, Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer, *Neoplasma.* (2007), 54(5):365-373.
- [25] C.I. Sartor, Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family, *Semin Oncol.* (2000), 27:15-20. discussion 92-100.
- [26] S. Roperio, J. Menendez, A. Vazquez-Martin, Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma, *Breast Cancer Res Treat.* (2004), 86:125-137.
- [27] S. Aifa, and A. Rebai, ErbB antagonists patenting: playing chess with cancer, *Recent Patents on Biotechnology.* (2008), 2(3):181-187.
- [28] E. Bandrés, R. Barricarte, and C. Cantero, Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients, *Oral Oncology.* (2007), (43) 7:713-719.
- [29] N. Hynes and H. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. *Nat Rev Cancer.* (2005), 5:341-354. doi: 10.1038/nrc1609.
- [30] K. Fallon, C. Palmer, K. Roth, L. Nabors, W. Wang, M. Carpenter, R. Banerjee, P. Forsyth, K. Rich, and A. Perry, Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas, *J Neuropathol Exp Neurol.* (2004), 63:314-322.
- [31] A. Marquez, R. Wu, J. Zhao, J. Tao, and Z. Shi, Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy, *Diagn Mol Pathol.* (2004), 13:1-8.
- [32] F. Cappuzzo, F. Hirsch, E. Rossi, S. Bartolini, G. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, and I. Domenichini, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, *J Natl Cancer Inst.* (2005), 97:643-655.
- [33] T. Takehana, K. Kunitomo, S. Suzuki, K. Kono, H. Fujii, Y. Matsumoto, and A. Ooi, Expression of epidermal growth factor receptor in gastric carcinomas, *Clin Gastroenterol Hepatol.* (2003), 1:438-445.
- [34] K. Al-Kuraya, P. Schraml, J. Torhorst, C. Tapia, B. Zaharieva, H. Novotny, H. Spichtin, R. Maurer, M. Mirlacher, and O. Kochli, Prognostic relevance of gene amplifications and coamplifications in breast cancer, *Cancer Res.* (2004), 64:8534-8540.
- [35] C. Corzo, I. Tusquets, M. Salido, J. Corominas, M. Bellet, M. Suarez, T. Baro, X. Fabregat, S. Serrano, and F. Sole, Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry, *Tumour Biol.* (2005), 26:25-30.
- [36] S. Paik, J. Bryant, and C. Park, erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer, *J Natl Cancer Inst.* (1998), 90:1361-1370.
- [37] M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, and A. Lluch, Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 study group, *J Clin Oncol.* (2005), 23:4265-4274.
- [38] W. Tao, C. Wang, R. Han, and H. Jiang, HER2 Codon 655 polymorphism and breast cancer risk: a meta-analysis, *Breast Cancer Res Treat.* (2009), 114(2):371-6.
- [39] S. Lu, Z. Wang, H. Liu, and X. Hao, HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies, *Breast Cancer Res Treat.* (2010), 124(3):771-8.
- [40] D. Xie, X. O. Shu, Z. Deng, W. Q. Wen, K. E. Creek, Q. Dai, Y. T. Gao, F. Jin, and W. Zheng, Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk, *J. Natl. Cancer Inst.* (Bethesda), (2000), 92:412-417.
- [41] L. Kruszyna, M. Lianeri, A. Roszak, and P. Jagodziński, HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma, *Clin Biochem.* (2010), 43(6):545-8.
- [42] R. Millikan, A. Eaton, K. Worley, L. Biscocho, E. Hodgson, W.Y. Huang, J. Geradts, M. Iacocca, D. Cowan, K. Conway, and L. Dressler, HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites, *Breast Cancer Res Treat.* (2003), 79:355-364.
- [43] S. Baxter, and I. Campbell, Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk, *J Natl Cancer Inst.* (2001), 98:557-558.
- [44] S.T. Lee-Hoeflich, L. Crocker, and E. Yao, A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy, *Cancer Res.* (2008), 68:5858-5887.
- [45] K. Montgomery, D. Gertig, S. Baxter, R. Milne, G. Dite, and M. McCredie, The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years, *Cancer Epidemiol Biomarkers Prev.* (2003), 12:1109-1111.
- [46] O. Ozturk, E. Canbay, O.T. Kahraman, M. Fatih Seyhan, F. Aydogan, V. Celik, and C. Uras, HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer, (2012), *Mol Biol Rep.* Oct 21. [Epub ahead of print].
- [47] I. Dahabreh, and S. Murray, Lack of replication for the asso-

- ciation between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis, *Cancer Epidemiol.* (2011), 35(6):503-9.
- [48] N. Kara, N. Karakus, A. Ulusoy, C. Ozaslan, B. Gungor, and H. Bagci, P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients, *DNA Cell Biol.* (2010), 29(7):387-92.
- [49] Y. Ma, J. Yang, P. Zhang, Z. Liu, Z. Yang, and H. Qin, Lack of association between HER2 Codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects, *Breast Cancer Res Treat.* (2011), 125(1):237-41.
- [50] R. Naidu, C. Yip, and N. Taib, Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases, *Neoplasma.* (2008), 55(2):87-95.
- [51] I. Kallel, M. Rebai, A. Khabir, N. Farid, and A. Rebaï, Genetic Polymorphisms in the EGFR (R521K) and Estrogen Receptor (T594T) Genes, EGFR and ErbB-2 Protein Expression, and Breast Cancer Risk in Tunisia, *J Biomed Biotechnol.* (2009), 753683.
- [52] S. M. Pupa, S. Menard, D. Morelli, The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage, *Oncogene.* (1993), 8:2917-2923.
- [53] N. Satiroglu-Tufan, F. Bir, and N. Calli-Demirkan, Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients, *World J Gastroenterol.* (2006), 28; 12(20):3283-7.
- [54] M.M. Moasser, The oncogene HER2; Its signaling and transforming functions and its role in human cancer pathogenesis *Oncogene.* (2007), 4; 26(45):6469-6487.
- [55] B. Hendriks, L. Opresko, H. Wiley, and D. Lauffenburger, Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels, *J Biol Chem.* (2003a), 278:23343-23351.
- [56] D. Karunakaran, E. Tzahar, R. Beerli, X. Chen, D. Graus-Porta, and B. Ratzkin, ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer, *EMBO J.* (1996), 15:254-264.
- [57] A. Lenferink, R. Pinkas-Kramarski, M. van de Poll, M. Van Vugt, L. Klapper, and E. Tzahar, Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers, *EMBO J.*; (1998), 17:3385-3397.
- [58] P. Siegel, E. Ryan, R. Cardiff, and W. Muller, Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer, *EMBO J.* (1991), 18:2149-2164.
- [59] D. Reissig, J. Clement, J. Sanger, A. Berndt, H. Kosmehl, and F. D. Bohmer, Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue, *J Cancer Res Clin Oncol.* (2001), 127:226-230.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

